Stock Analiz

Bio Key International Inc. BKYI

Computer Software: Prepackaged Software · data as of November 13, 2026

$2.12Market cap $4M
Open the interactive analysis →

Bio Key International Inc. (BKYI) is a technology company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $7M and net income of -$6M, a net margin of -89.8%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 16% a year, a 5-year average ROIC of -201%.

About Bio Key International

Bio Key International is listed in the US and classified in computer software: prepackaged software. Revenue went from $4M in 2014 to $6M in 2025, growth of about 3.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 52% over three years (dilution for shareholders). It spends 44% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E15.1
P/FCF—
P/S0.7
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-103.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-14.3%
Revenue growth (5 yrs, per year)15.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-112.2%
ROIC (5-yr avg.)-201.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$7M$6M$7M$8M$7M$5M$3M$2M$4M$6M$3M
Net income-$6M-$7M-$4M-$9M-$12M-$5M-$10M-$15M-$7M-$4M-$4M
Free cash flow-$4M-$5M-$3M-$4M-$6M-$9M-$5M-$2M-$2M-$3M-$4M
EPS (diluted)$-3.56$-3.59$-6.96$-5.07$-9.09$-0.22$-0.69$-2.74$-1.95$-2.03$-2.37
Net margin-89.8%-120.5%-62.1%-109.9%-169.6%-99.1%-341.0%-643.4%-169.8%-67.8%-140.8%
ROIC—-104.6%-102.6%-608.1%-166.6%-24.6%-19.5%-158.9%0.0%-24.6%-21.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $20.00, 843% above the current price; targets range from $20.00 to $20.00; the consensus rating is “none”; expected EPS is $-1.62 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Bio Key International pay a dividend?

Not currently.

Is Bio Key International a good stock to buy?

We do not give buy or sell advice. Bio Key International scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.